Back to the Future: In the Era of Cost-Effectiveness Analysis, Affordability Is a Limiting Factor for Patients' Access to Innovative Cancer Treatments
ConclusionsWe conclude that because of the socioeconomic inequality mostly seen in lower and middle-income countries, it is difficult to define a cost-effectiveness threshold by region or a willingness-to-pay threshold affordable to the entire population. We consider that benchmark interventions might help to find an affordable willingness-to-pay threshold, and league table interventions might help policy makers, physicians, and the society to share the decision making.
Source: Value in Health Regional Issues - Category: International Medicine & Public Health Source Type: research
More News: Brazil Health | Cancer | Cancer & Oncology | Cancer Therapy | Health Insurance | Insurance | International Medicine & Public Health